|
PLEKHA9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62436730732907E-12 |
| Normal-vs-Stage2 |
7.80230000000381E-05 |
| Normal-vs-Stage3 |
1.70974345792274E-13 |
| Normal-vs-Stage4 |
2.50209999996809E-06 |
| Stage1-vs-Stage2 |
7.054600E-01 |
| Stage1-vs-Stage3 |
3.542200E-01 |
| Stage1-vs-Stage4 |
1.008630E-01 |
| Stage2-vs-Stage3 |
8.662600E-01 |
| Stage2-vs-Stage4 |
4.071400E-01 |
| Stage3-vs-Stage4 |
3.306200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62436730732907E-12 |
| Normal-vs-AfricanAmerican |
6.696700E-03 |
| Normal-vs-Asian |
4.87189999454074E-08 |
| Caucasian-vs-AfricanAmerican |
6.656500E-02 |
| Caucasian-vs-Asian |
9.603800E-01 |
| AfricanAmerican-vs-Asian |
1.083570E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.8746783559418E-14 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
4.959400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(61-80Yrs) |
1.84759996191275E-09 |
| Normal-vs-Age(81-100Yrs) |
3.218300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.925400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.345800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.741000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.025760E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.054200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.341600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.477850E-02 |
| Classical-VS-Follicular |
1.217400E-04 |
| Classical-VS-Other |
7.052400E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
1.787640E-01 |
| Tall-VS-Other |
3.245400E-01 |
| Tall-VS-Normal |
1.97330000117901E-08 |
| Follicular-VS-Other |
1.148780E-01 |
| Follicular-VS-Normal |
6.40410000000147E-05 |
| Other-VS-Normal |
2.283700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.73430000027786E-07 |
| N0-vs-N1 |
3.015800E-01 |
|
|
